Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference

SAN DIEGO, May 16, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), on May 23 at the American Thoracic Society (ATS) 2017 International Conference. The conference is taking place May 19-24 at the Walter E. Washington Convention Center in Washington, D.C. 

The presentation will comprise single and multiple ascending dose Phase 1 data highlighting the safety and pharmacokinetics of ralinepag in healthy volunteers. 

"The Phase 1 clinical data supports our belief that ralinepag is a potential best-in-class oral prostacyclin therapy," said Amit Munshi, Arena's President and Chief Executive Officer. "The acceptance of the scientific data presentation at ATS underscores the enthusiasm on the part of clinical investigators to continue to explore the novel profile of ralinepag."

Presentation Details

Title: Safety and Pharmacokinetics of Ralinepag (APD811), a Next-generation, Selective Prostacyclin Receptor Agonist, in Healthy Adult Subjects
Date/Time: Tuesday, May 23, 2017, from 2:15 – 4:15 p.m. EDT
Abstract Number: #12519
Poster Session: C106

About Arena Pharmaceuticals
At Arena, we are focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights.  Our three most advanced investigational clinical programs are ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune indications, and APD371 in Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation, the potential of ralinepag, advancement of our pipeline, our focus, and the potential of our programs and collaborations.  For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from our expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in our filings with the Securities and Exchange Commission. These forward-looking statements represent our judgment at of the time of this release. We disclaim any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact:
Arena Pharmaceuticals, Inc. 
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-phase-1-data-on-ralinepag-for-treatment-of-pulmonary-arterial-hypertension-at-the-american-thoracic-society-2017-international-conference-300458791.html

SOURCE Arena Pharmaceuticals, Inc.